Ubs Oconnor LLC Mirati Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

  • $1.46 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$27.8 - $45.35 $139,000 - $226,750
5,000 Added 8.38%
64,698 $2.82 Million
Q2 2023

Aug 14, 2023
BUY
$36.13 - $49.49 $2.16 Million - $2.95 Million
59,698 New
59,698 $2.16 Billion
Q1 2023

May 15, 2023
BUY
$36.54 - $54.26 $45,675 - $67,825
1,250 Added 2.72%
47,250 $1.76 Million
Q4 2022

Feb 14, 2023
BUY
$41.27 - $98.62 $1.9 Million - $4.54 Million
46,000 New
46,000 $0

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email